Consensus classification of pediatric hepatocellular tumors: A report from the Children's Hepatic tumors International Collaboration (CHIC).
hepatoblastoma
international clinical trial
liver tumors
pediatric
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
29 Jun 2023
29 Jun 2023
Historique:
revised:
15
05
2023
received:
25
08
2022
accepted:
02
06
2023
medline:
29
6
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
aheadofprint
Résumé
Liver tumors are rare in children with histologic heterogeneity that makes diagnosis challenging. Systematic histopathological review, performed as part of collaborative therapeutic protocols, identified relevant histologic subtypes that are important to distinguish. The Children's Hepatic tumors International Collaboration (CHIC) was established to study pediatric liver tumors on a global scale and led to establishment of a provisional consensus classification for use in international clinical trials. The current study is the validation of this initial classification and first large-scale application by international expert reviewers. The CHIC initiative includes data from 1605 children treated on eight multicenter hepatoblastoma (HB) trials. Review of 605 available tumors was performed by seven expert pathologists from three consortia (US, EU, Japan). Cases with discordant diagnoses were collectively reviewed to reach a final consensus diagnosis. Of 599 cases with sufficient material for review, 570 (95.2%) were classified as HB by all consortia, and 29 (4.8%) as non-HB, which included "hepatocellular neoplasm, NOS" and malignant rhabdoid tumors. 453 of 570 HBs were classified as epithelial by final consensus. Some patterns (i.e., small cell undifferentiated, macrotrabecular, cholangioblastic) were selectively identified by reviewers from different consortia. All consortia identified a similar number of mixed epithelial-mesenchymal HB. This study represents the first large-scale application and validation of the pediatric malignant hepatocellular tumors consensus classification. It is a valuable resource to train future generations of investigators on accurate diagnosis of these rare tumors and provides a framework for further international collaborative studies and refinement of the current classification of pediatric liver tumors.
Sections du résumé
BACKGROUND
BACKGROUND
Liver tumors are rare in children with histologic heterogeneity that makes diagnosis challenging. Systematic histopathological review, performed as part of collaborative therapeutic protocols, identified relevant histologic subtypes that are important to distinguish. The Children's Hepatic tumors International Collaboration (CHIC) was established to study pediatric liver tumors on a global scale and led to establishment of a provisional consensus classification for use in international clinical trials. The current study is the validation of this initial classification and first large-scale application by international expert reviewers.
PROCEDURE
METHODS
The CHIC initiative includes data from 1605 children treated on eight multicenter hepatoblastoma (HB) trials. Review of 605 available tumors was performed by seven expert pathologists from three consortia (US, EU, Japan). Cases with discordant diagnoses were collectively reviewed to reach a final consensus diagnosis.
RESULTS
RESULTS
Of 599 cases with sufficient material for review, 570 (95.2%) were classified as HB by all consortia, and 29 (4.8%) as non-HB, which included "hepatocellular neoplasm, NOS" and malignant rhabdoid tumors. 453 of 570 HBs were classified as epithelial by final consensus. Some patterns (i.e., small cell undifferentiated, macrotrabecular, cholangioblastic) were selectively identified by reviewers from different consortia. All consortia identified a similar number of mixed epithelial-mesenchymal HB.
CONCLUSIONS
CONCLUSIONS
This study represents the first large-scale application and validation of the pediatric malignant hepatocellular tumors consensus classification. It is a valuable resource to train future generations of investigators on accurate diagnosis of these rare tumors and provides a framework for further international collaborative studies and refinement of the current classification of pediatric liver tumors.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30505Subventions
Organisme : European Network for Cancer Research in Children and Adolescents
ID : 261474
Organisme : Hepatoblastoma Foundation
Organisme : Japan Agency for Medical Research and Development
ID : 17ck0106332h0001
Organisme : Japan Society for the Promotion of Science
ID : JP16H02778
Organisme : Madeleine Schickedanz pediatric cancer foundation
Organisme : Swiss Cancer Research
ID : KFS-3936-08-2016
Organisme : Children's Liver Tumour European Research Network
ID : 668596
Informations de copyright
© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Czauderna P, Haeberle B, Hiyama E, et al. The Children's Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92-101. 10.1016/j.ejca.2015.09.023
Haeberle B, Rangaswami A, Krailo M, et al. The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: analysis from the Children's Hepatic tumors International Collaboration (CHIC) database. Pediatr Blood Cancer. 2020;67(8):e28350. 10.1002/pbc.28350
Meyers RL, Maibach R, Hiyama E, et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol. 2017;18(1):122-131. 10.1016/S1470-2045(16)30598-8
Lopez-Terrada D, Alaggio R, de Davila MT, et al. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol. 2014;27(3):472-491. 10.1038/modpathol.2013.80
Gonzalez-Crussi F. Undifferentiated small cell (“anaplastic”) hepatoblastoma. Pediatr Pathol. 1991;11(1):155-161. 10.3109/15513819109064752
Haas JE, Feusner JH, Finegold MJ. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer. 2001;92(12):3130-3134. 10.1002/1097-0142(20011215)92:12<3130::aid-cncr10115>3.0co;2-#
Meyers RL, Rowland JR, Krailo M, Chen Z, Katzenstein HM, Malogolowkin MH. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;53(6):1016-1022. 10.1002/pbc.22088
Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, Gore L, Feusner JH. Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer. 2009;52(3):328-334. 10.1002/pbc.21834
Trobaugh-Lotrario A, Katzenstein HM, Ranganathan S, et al. Small cell undifferentiated histology does not adversely affect outcome in hepatoblastoma: a report from the Children's Oncology Group (COG) AHEP0731 Study Committee. J Clin Oncol. 2022;40(5):459-467. 10.1200/JCO.21.00803
Trobaugh-Lotrario AD, Maibach R, Aronson DC, et al. Outcomes of patients treated for hepatoblastoma with low alpha-fetoprotein and/or small cell undifferentiated histology: a report from the Children's Hepatic Tumors International Collaboration (CHIC). Cancers (Basel). 2023;15(2):467. 10.3390/cancers15020467
Ranganathan S, Lopez-Terrada D, Alaggio R. Hepatoblastoma and pediatric hepatocellular carcinoma: an update. Pediatr Dev Pathol. 2020;23(2):79-95. 10.1177/1093526619875228
Manivel C, Wick MR, Abenoza P, Dehner LP. Teratoid hepatoblastoma. The nosologic dilemma of solid embryonic neoplasms of childhood. Cancer. 1986;57(11):2168-2174. 10.1002/1097-0142(19860601)57:11<2168::aid-cncr2820571115>3.0.co;2-m
Rabah R. Teratoid hepatoblastoma with abundant neuroendocrine and squamous differentiation with extensive parenchymal metastasis. Arch Pathol Lab Med. 2012;136(8):911-914. 10.5858/arpa.2012-0212-CR
Berklite L, Ranganathan S. Teratoid hepatoblastoma-our experience. Cancers (Basel). 2022;14(24):6135. 10.3390/cancers14246135
Gonzalez-Crussi F, Upton MP, Hepatoblastoma MaurerHS. Attempt at characterization of histologic subtypes. Am J Surg Pathol. 1982;6(7):599-612.
Sumazin P, Peters TL, Sarabia SF, et al. Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. J Hepatol. 2022;77:1026-1037. 10.1016/j.jhep.2022.04.035
Eichenmuller M, Trippel F, Kreuder M, et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol. 2014;61(6):1312-1320. 10.1016/j.jhep.2014.08.009
Nagae G, Yamamoto S, Fujita M, et al. Genetic and epigenetic basis of hepatoblastoma diversity. Nat Commun. 2021;12(1):5423. 10.1038/s41467-021-25430-9
Zimmermann A. Hepatoblastoma with cholangioblastic features (‘cholangioblastic hepatoblastoma’) and other liver tumors with bimodal differentiation in young patients. Med Pediatr Oncol. 2002;39(5):487-491. 10.1002/mpo.10173